$7.71
▼ -2.0% Today
as of Sep 4, 16:52 ET
Last 30 days
Recent Press Releases & News
OptimizeRx Appoints Pharma Commercialization and AI Expert Troy Sarich as Company Advisor
OptimizeRx (OPRX) Q2 2026 Earnings Call Transcript
OptimizeRx Corporation Q2 2026 Earnings Call Summary
Overview
52-week range
$4.54
$22
18% of range
Avg surprise (last 3)
+170.4%
Avg reaction (last 2)
-2.9%
50% positive
Latest IV / EM
94%
EM ±14.6% · $8 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-0.04 | — | — | — | — | financials |
| Tue May 12, 2026 | Mar/2026 | $0.03 | $-0.09 | +133.3% | — | +2.1% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $0.04 | — | — | — | — | financials |
| Thu Aug 7, 2025 | Jun/2025 | $0.16 | $-0.09 | +277.8% | — | — | earnings |
| Mon May 12, 2025 | Mar/2025 | — | $-0.27 | +100.0% | — | -7.9% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.50 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.22 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.38 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.17 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.24 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $-0.37 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $21M | $20M | — | $26M | $29M | $22M | — | $21M |
| Cost of revenue | $5M | $5M | — | $9M | $11M | $9M | — | $8M |
| Gross profit | — | — | — | $18M | $19M | $13M | — | $13M |
| Operating income | $-88,000 | $396,000 | — | $2M | $3M | $-2M | — | $-9M |
| Net income | $-703,000 | $-495,000 | — | $779,000 | $2M | $-2M | — | $-9M |
| EPS (diluted) | $-0.04 | $-0.03 | — | $0.04 | $0.08 | $-0.12 | — | $-0.50 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $24M | $20M | $23M | $20M | $17M | $17M | $13M | $16M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $54M | $56M | $65M | $56M | $54M | $52M | $54M | $47M |
| Total assets | $164M | $167M | $177M | $170M | $169M | $168M | $171M | $165M |
| Long-term debt | $18M | $21M | $21M | $25M | $25M | $29M | $31M | $33M |
| Total liabilities | $33M | $38M | $49M | $48M | $50M | $51M | $54M | $51M |
| Total equity | $131M | $130M | $128M | $122M | $119M | $116M | $117M | $114M |